• Preclinical work on calcium oxalate inhibitors for renal indications published

    We are thrilled to have published data in Advanced Science that further validates the therapeutic potential of IP6 analogs from Inositec’s InosituneTM platform in calcification disorders, here in the context of calcium oxalate crystal-related diseases. Calcium oxalate is the most common component of kidney stones.

    This entry was posted in News. Bookmark the permalink.